FOLH1 and metastatic neoplasm: The TheraP trial requested an SUVmax on PSMA-PET of at least 20 at a site of disease and greater than 10 at all other measurable metastases, and no presence of metastatic disease with discordant, i.e. 2-[18F]FDG-positive and PSMA-negative findings [20].